- Home
- TARS vs CHRN Comparison
TARS vs CHRN Comparison
Compare TARS & CHRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARS | CHRN |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.2B |
| IPO Year | 2020 | 2012 |
Fundamental Metrics
Financial Performance| Metric | TARS | CHRN |
|---|---|---|
| Price | $78.18 | $18.68 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $89.00 | N/A |
| AVG Volume (30 Days) | ★ 705.3K | 147.3K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | 48.21 | ★ 92.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $451,360,000.00 | N/A |
| Revenue This Year | $56.43 | N/A |
| Revenue Next Year | $30.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 146.71 | N/A |
| 52 Week Low | $48.79 | $15.74 |
| 52 Week High | $91.53 | $30.00 |
Technical Indicators
Market Signals| Indicator | TARS | CHRN |
|---|---|---|
| Relative Strength Index (RSI) | 58.64 | 43.49 |
| Support Level | $77.14 | $16.72 |
| Resistance Level | $84.66 | $24.97 |
| Average True Range (ATR) | 3.77 | 2.01 |
| MACD | -0.04 | -0.11 |
| Stochastic Oscillator | 47.52 | 21.36 |
Price Performance
Historical ComparisonAbout TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
About CHRN ChronoScale Corporation Common Stock
ChronoScale Corp is focused on providing computing infrastructure for artificial intelligence workloads. It offers GPU-based infrastructure for AI training, inference, and high-performance computing.